ROS1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis

In the article published by Zhou et al. [1], it was identified a novel ROS1 mutation type namely G2032  K in which mediated resistance to targeted therapy like lorlatinib in lung adenocarcinoma. They suggested that immune checkpoint inhibitors (ICIs) plus chemotherapy could be considered as an option for patients harboring ROS1 mutations after acquired resistance to targeted therapies. Nevertheless , it was unknown whether the patient with ROS1 mutations would obtain clinical benefit from ICIs treatment alone.

Source: Lung Cancer - August 3, 2020 Category: Cancer & Oncology Authors: Xuanzong Li, Linlin Wang, Jinming Yu Source Type: research